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After a radiological incident, there is an urgent need for fast and reliable bioassays to identify radiation-
exposed individuals within the first week post exposure. This study aimed to identify candidate 
radiation-responsive protein biomarkers in human lymphocytes in vivo using humanized NOD scid 
gamma (Hu-NSG) mouse model. Three days after X-irradiation (0–2 Gy, 88 cGy/min), human CD45+ 
lymphocytes were collected from the Hu-NSG mouse spleen and quantitative changes in the proteome 
of the human lymphocytes were analysed by mass spectrometry. Forty-six proteins were differentially 
expressed in response to radiation exposure. FDXR, BAX, DDB2 and ACTN1 proteins were shown to 
have dose-dependent response with a fold change greater than 2. When these proteins were used to 
estimate radiation dose by linear regression, the combination of FDXR, ACTN1 and DDB2 showed 
the lowest mean absolute errors (≤0.13 Gy) and highest coefficients of determination (R2 = 0.96). 
Biomarker validation studies were performed in human lymphocytes 3 days after irradiation in vivo and 
in vitro. In conclusion, this is the first study to identify radiation-induced human protein signatures in vivo  
using the humanized mouse model and develop a protein panel which could be used for the rapid 
assessment of absorbed dose 3 days after radiation exposure.
In the event of a radiological attack or accidental exposure, it will be necessary to quickly identify exposed victims 
from non-exposed groups and predict their received dose for effective medical treatment. In a mass-casualty 
scenario, a large number of people can be exposed to a wide range of radiation doses. It will be crucial to collect 
and analyze human biofluids (such as blood, urine, saliva) as soon as possible within the first week for accurate 
dose prediction and early triage decision. The applicability of potentially available biodosimetry methods for 
triage in large-scale radiation events was recently assessed1. Based on an updated comparative framework of six 
biodosimetry methods, increased population size, along with severely compromised infrastructure will increase 
the time needed to perform triage, which in turn will decrease the usefulness of many time intensive dosime-
try methods. Therefore, this highlights the challenging need for the identification and development of potential 
diagnostic biomarkers for use as radiation biodosimeters of human exposure in vivo to ionizing radiation in 
terms of time- and dose-dependent response and high throughput capability, days after initial radiation expo-
sure2,3. The rapid immunodetection of radiation responsive protein markers have potential as a useful diagnostic 
tool for the mass-screening of potentially exposed individuals. Earlier studies have suggested various radiation 
responsive proteins as candidate biomarkers for radiation biodosimetry4–7. However, the fact that DNA damage 
related proteins such as ATM and H2AX show increased amounts or changes in phosphorylation states within 
24 h after exposure, limits their use as radiation biodosimeters for extended time points after initial radiation 
exposure4. Recently, Hall and colleagues5, provided a roadmap for developing biomarkers of radiation exposure 
from discovery to implementation to summarize the current status of proposed ionizing radiation biomarkers for 
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epidemiological studies. This extensive review highlighted that most potential biomarkers remain at the discovery 
stage and require robust validation studies.
To date, the development and validation of radiation biomarkers in vivo has relied heavily on mouse models 
and more recently non-human primate (NHP) models due to the limitation in obtaining appropriate human sam-
ples8,9. Few studies have systematically validated radio-responsive human protein markers in vivo for dose- and 
time-response after radiation exposure. Radiation responsive plasma proteins such as Flt3 ligand (Flt3L), serum 
amyloid A (SAA) and Interleukin-6 (IL-6) have been studied in mouse models as markers of acute radiation 
syndrome and radiation exposure up to a week10,11. Using the NHP model, C-reactive protein (CRP), SAA, IL-6, 
Flt3L protein biomarkers expressed in NHP plasma have been proposed as early indicators of dose assessment 
and radiation-induced injury up to ~7 days post irradiation12,13. Recently, proteomics-based technology has been 
used to discover novel biomarkers for radiation biodosimetry in NHP models14,15.
The humanized mouse model provides an alternative model to study in vivo human biological response. 
This model is being increasingly used as a preclinical model in multiple biological fields including infectious 
diseases, immunology, cancer, regenerative medicine, hematology, and autoimmunity16–18. NOD-scid IL2rγnull 
mice (NOG/NSG) are known to support higher engraftment with human CD34+ hematopoietic stem cells 
(HSCs) compared to BALB/c and CB17 scid strains16. The transplantation of HSCs derived from bone mar-
row, umbilical cord blood (UBC), or G-CSF–mobilized peripheral blood leads to the development of human 
hematopoietic progenitor and differentiated cells in the mouse bone marrow, spleen and thymus, culminating 
in a functional human immune system17,19–21. Recently, Wang et al. investigated the effects of ionizing radia-
tion on human HSC cells22,23. Their results showed that radiation exposure induces DNA damage observed as 
γ-H2AX foci formation in the HSCs and promotes their aging-like phenotypic changes in the bone marrow 
microenvironment.
In the present study, we used the Hu-NSG mouse model to identify novel radiation-responsive candidate 
protein biomarkers in human lymphocytes in vivo for biodosimetry developmental studies. We applied shotgun 
proteomics to evaluate proteome-wide changes in human CD45+ B and T cells, 3 days after X-ray exposure 
(Fig. 1; workflow). Presented here are our top 4 protein candidate biomarkers and a panel of radiation responsive 
proteins to predict absorbed dose.
Figure 1. Experimental workflow to identify and validate candidate protein markers for radiation exposure 
using humanized mouse model. (A) Humanized mice were generated by injecting commercially available 
human cord blood CD34+ cells through the tail veins of NSG mice. Human cell engraftment was determined 
by measuring human CD45, human CD20, and human CD3 positive cells by flow cytometry 4–5 months after 
transplantation. Representative flow cytometry plots show the engraftment of human cells in non-irradiated 
humanized mice and hematopoietic reconstitution with human T and B cells in humanized mice. Humanized 
mice were then whole body-irradiated with X rays and the mouse spleen and blood were collected 3 days after 
irradiation. (B) Human cells were isolated from spleen tissues and analysed with isobaric tandem mass tag 
(TMT) labeled LC-MS/MS global proteome profiling. (C) Candidate protein expression levels were quantified 
in human CD45+ lymphocytes by immunofluorescence staining.
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Results
Reconstitution of human hematopoietic cells in humanized mice. Ninety-seven percentage of 
recipient NSG mice showed successful engraftment 4–5 months after injection of HSCs. Figure 1A shows repre-
sentative flow cytometry plots for human hematopoietic cell reconstitution from a humanized mouse tail blood 
prior to irradiation. The humanized mice (n = 33) generated in this study had 61.3 ± 17.9% human CD45+ cells 
including human B and T cells. Blood cell characteristics for each individual humanized mouse are detailed in 
Supplementary Table S1. Supplementary Fig. S1 shows the total number of human CD45+ cells across the three 
dose groups before and after irradiation. The results show similar proportion of human B and T cells with no 
statistically significant difference (p > 0.05) across each group before irradiation (Supplementary Fig. S1A). Since 
X rays dramatically decreased human lymphocyte cell number (Supplementary Fig. S1B), flow-sorted human 
CD45+ cells from mice injected with the same human HSCs were pooled in order to obtain sufficient amounts 
of protein for proteomic analysis.
Protein signatures in X-irradiated human lymphocytes 3 days after exposure. In total, 3,376 
human proteins were identified based on 5% false discovery rate (FDR) at the protein level. In comparison 
of three different radiation dose groups, 34 proteins were found to be statistically significant at 0.001% FDR 
(Supplementary Table S2). Hierarchical clustering analysis and Principal Component Analysis (PCA) of these 
34 proteins showed that the protein expression profiling can be separated into non-irradiated and irradiated 
clusters (Fig. 2A,B). Comparisons between 0 Gy vs 1 Gy (0.010% FDR; Fig. 2C) and 0 Gy vs 2 Gy (0.023% FDR, 
Fig. 2D) revealed a good separation according to radiation exposure and identified further 12 radiation respon-
sive proteins.
Selection of candidate protein markers for radiation biodosimetry. The 46 differential radiation 
responsive proteins identified above are presented in Table 1 according to fold changes after 1 Gy and 2 Gy irra-
diation. The results show that a total of 28 proteins were up-regulated and 18 proteins were down-regulated. Of 
the 28 up-regulated proteins, 6 showed a fold change >2 (TSPYL2, FDXR, GMPR2, ACTN1, BAX and DDB2) for 
both doses. Of the 18 down-regulated proteins, 3 proteins (HBA1, HBB and HMGN4) showed a high response to 
radiation with a fold change >2. To test the dose dependent response, the correlation between protein expression 
Figure 2. Statistical analysis of the proteome from human lymphocytes, isolated from humanized mice 3 days 
after irradiation. (A) Heat map showed a distinct protein signature between the non-irradiated group and 
irradiated groups at 0.001% of the false discovery rate (FDR) using ANOVA. Principal component analysis 
(PCA) plots showed comparisons of (B) three different dose groups (0, 1 and 2 Gy) at 0.001% FDR, (C) two 
dose groups (0 Gy and 1 Gy) at 0.010% FDR and, (D) two dose groups (0 Gy and 2 Gy) at 0.023%. Black dashed 
circle and solid circle represent clusters of non-irradiated and irradiated groups, respectively. A detailed protein 
list is included in Supplementary Table S2.
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Accession no. Protein name (Gene symbol)
Fold changea




Q9H2G4 Testis-specific Y-encoded-like protein 2 (TSPYL2) 14.97 ± 5.50 15.26 ± 5.69 3.81E-12c
P22570 NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR) 2.85 ± 0.23 3.47 ± 0.33 6.70E-11c
H0YNJ6 GMP reductase (GMPR2) 2.23 ± 0.16 2.59 ± 0.17 1.94E-09c
P12814 Alpha-actinin-1 (ACTN1) 2.03 ± 0.13 2.56 ± 0.14 1.01E-09c
Q07812 Apoptosis regulator BAX (BAX) 2.32 ± 0.28 2.37 ± 0.17 8.96E-09c
Q92466 DNA damage-binding protein 2 (DDB2) 2.04 ± 0.20 2.21 ± 0.18 1.12E-08c
Q8WWP7 GTPase IMAP family member 1 (GIMAP1) 1.89 ± 0.23 2.02 ± 0.33 1.39E-08c
Q6UXH1 Cysteine-rich with EGF-like domain protein 2 (CRELD2) 1.62 ± 0.10 2.01 ± 0.26 1.73E-08c
Q9NRX4 14 kDaphosphohistidine phosphatase (PHPT1) 1.77 ± 0.19 1.93 ± 0.22 2.73E-09e
P06127 T-cell surface glycoprotein CD5 (CD5) 1.75 ± 0.12 1.82 ± 0.23 1.43E-08c
P04083 Annexin A1 (ANXA1) 1.20 ± 0.06 1.73 ± 0.15 2.44E-08e
Q01831 DNA repair protein complementing XP-C cells (XPC) 1.29 ± 0.10 1.58 ± 0.12 2.19E-07e
P21291 Cysteine and glycine-rich protein 1 (CSRP1) 1.49 ± 0.10 1.52 ± 0.14 4.73E-07e
P17612 cAMP-dependent protein kinase catalytic subunit alpha (PRKACA) 1.28 ± 0.09 1.52 ± 0.02 2.28E-09
c
A0A087WZM2 Ribonuclease T2 (RNASET2) 1.26 ± 0.05 1.48 ± 0.10 2.98E-09c
P08311 Cathepsin G (CTSG) 1.64 ± 0.20 1.44 ± 0.13 2.71E-08d
Q9UHD8 Septin-9 (SEPT9) 1.22 ± 0.06 1.36 ± 0.07 4.09E-08c
Q96HC4 PDZ and LIM domain protein 5 (PDLIM5) 1.21 ± 0.09 1.34 ± 0.08 1.73E-08e
P19367 Hexokinase-1 (HK1) 1.09 ± 0.05 1.34 ± 0.09 2.02E-08c
P08133 Annexin A6 (ANXA6) 1.15 ± 0.06 1.30 ± 0.05 4.20E-08c
P21283 V-type proton ATPase subunit C 1 (ATP6V1C1) 1.26 ± 0.09 1.29 ± 0.07 1.74E-07e
P48426 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (PIP4K2A) 1.30 ± 0.06 1.25 ± 0.05 1.04E-07
d
P20073 Annexin A7 (ANXA7) 1.15 ± 0.06 1.24 ± 0.07 1.12E-07e
P46777 60 S ribosomal protein L5 (RPL5) 1.09 ± 0.13 1.23 ± 0.18 1.46E-06e
O75083 WD repeat-containing protein 1 (WDR1) 1.14 ± 0.05 1.21 ± 0.07 1.98E-08c
Q9Y490 Talin-1 (TLN1) 1.20 ± 0.05 1.20 ± 0.06 5.18E-08c
A0A024R4M0 40 S ribosomal protein S9 (RPS9) 1.30 ± 0.11 1.19 ± 0.11 3.00E-08d
A0A0A0MT22 Protein tyrosine phosphatase, receptor type, C, isoform CRA_d (PTPRC) 1.22 ± 0.05 1.10 ± 0.07 1.24E-07
d
Down-regulated proteins
P69905 Hemoglobin subunit alpha (HBA1) 10.91 ± 3.30 12.60 ± 2.94 4.44E-10c
P68871 Hemoglobin subunit beta (HBB) 9.64 ± 0.14 10.63 ± 1.31 4.92E-10c
O00479 High mobility group nucleosome-binding domain-containing protein 4 (HMGN4) 2.25 ± 0.14 2.16 ± 0.32 8.23E-08
c
E7EX17 Eukaryotic translation initiation factor 4B (EIF4B) 2.00 ± 0.19 1.89 ± 0.20 1.74E-08c
Q9Y2W1 Thyroid hormone receptor-associated protein 3 (THRAP3) 1.92 ± 0.21 1.83 ± 0.14 3.83E-11c
P62263 40 S ribosomal protein S14 (RPS14) 1.80 ± 0.29 1.82 ± 0.23 8.72E-08c
Q9NYF8 Bcl-2-associated transcription factor 1 (BCLAF1) 1.56 ± 0.10 1.82 ± 0.18 7.39E-09c
O15400 Syntaxin-7 (STX7) 1.76 ± 0.23 1.65 ± 0.16 3.34E-08c
D6RBZ0 Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB) 1.61 ± 0.12 1.62 ± 0.05 1.94E-11c
P38159 RNA-binding motif protein, X chromosome (RBMX) 1.56 ± 0.14 1.57 ± 0.09 6.49E-09c
P35611 Alpha-adducin (ADD1) 1.48 ± 0.11 1.46 ± 0.05 9.65E-08c
Q96PK6 RNA-binding protein 14 (RBM14) 1.36 ± 0.07 1.43 ± 0.06 4.91E-10c
O75400 Pre-mRNA-processing factor 40 homolog A (PRPF40A) 1.37 ± 0.07 1.42 ± 0.07 9.52E-09c
Q00839 Heterogeneous nuclear ribonucleoprotein U (HNRNPU) 1.28 ± 0.05 1.40 ± 0.08 4.29E-09c
X6R4W8 BUB3-interacting and GLEBS motif-containing protein ZNF207 (ZNF207) 1.25 ± 0.10 1.39 ± 0.13 1.57E-08
c
Q12874 Splicing factor 3 A subunit 3 (SF3A3) 1.22 ± 0.04 1.38 ± 0.09 1.27E-08c
Q13435 Splicing factor 3B subunit 2 (SF3B2) 1.24 ± 0.08 1.32 ± 0.08 3.35E-08c
Q9NR30 Nucleolar RNA helicase 2 (DDX21) 1.17 ± 0.03 1.29 ± 0.04 1.01E-08c
Table 1. List of differentially expressed proteins in vivo. aFold change compared to non-irradiated group was 
calculated and data represent mean ± SEM. bData were analysed using one-way ANOVA test. The details are 
included in Supplementary Table S2. cp value obtained from comparison of three dose groups (0, 1 and 2 Gy) 
was described. dp value obtained from comparison between 0 Gy vs. 1 Gy was described. ep value obtained from 
comparison between 0 Gy vs. 2 Gy was described.
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and irradiated dose was evaluated for all 46 radiation responsive proteins. Proteins with high correlation (|cor-
relation coefficient| > 0.70; p value < 0.05) are shown in Supplementary Table S3. The results show that the top 6 
upregulated proteins (TSPYL2, FDXR, GMPR2, ACTN1, BAX and DDB2) have high dose-dependent response to 
radiation. Humanized mice used in this study were generated by injecting five different human donors’ stem cells. 
Figure 3 shows the dose response curves for FDXR, BAX, DDB2 and ACTN1 from 5 different human donors, 
3 days after irradiation. These 4 proteins showed a dose-dependent response in human cells derived from each 
human donor. GMPR2 and TSPYL2 were not explored further as candidate biomarkers due to an incomplete 
data set caused by missing values and high variability between the donors. Although the top 3 down-regulated 
proteins (HBA1, HBB, HMGN4) showed fold changes >2, HBA1 and HBB had high variation between donors 
and HMGN4 did not show a dose-dependent response.
Dose Prediction of candidate protein markers. The top 4 upregulated proteins (FDXR, BAX, DDB2 
and ACTN1) were selected as the best candidates for dose predictions. Various combinations of these proteins 
were used to predict radiation dose by linear regression. In other words, levels of one or more of these proteins 
were used as predictor variables, whereas radiation dose was the outcome variable. Four models had substantial 
information theoretic support from the data, based on Akaike information criterion scores with sample size cor-
rection (AICc). They are shown in Table 2 and Supplementary Table S4. Those three models that included com-
binations of FDXR, ACTN1 and DDB2 had the strongest information theoretic support, lowest mean absolute 
errors (≤0.13 Gy) and highest coefficients of determination (R2 = 0.96) (Supplementary Table S4). The ability of 
each of these multi-protein models to predict dose is shown in Table 2, and the performance of various models 
containing only one protein is shown in Supplementary Table S5. These results suggest that FDXR and ACTN1 
had strong associations with radiation dose (for each of them the sum of Akaike weights across all tested models 
was 1.0) and represent potentially valuable radiation biomarkers. DDB2 had a somewhat weaker association with 
dose (sum of Akaike weights was 0.14) but may still be a useful predictor.
Verification of candidate protein markers in human lymphocytes in vivo/in vitro. Radiation- 
induced FDXR protein expression levels were evaluated in human CD45 + cells in vivo from the peripheral blood 
of the humanized mice (Fig. 4A). Representative images of FDXR protein observed in human CD45+ lympho-
cytes are shown after 2 Gy X-irradiation (Left panel in Fig. 4A). The results show a statistically significant increase 
in total FDXR fluorescence intensity in the 1 Gy and 2 Gy irradiated groups compared to the non-irradiated group 
(p value < 0.05; Right panel in Fig. 4A). Biomarker validation studies were also performed using human periph-
eral blood samples collected from up to 3-4 healthy human volunteers. The results show a significant increase in 
FDXR, ACTN1 and DDB2 protein levels in isolated human lymphocytes in vitro, 3 days after irradiation (Fig. 4B).
Figure 3. Radiation-induced changes in candidate protein expression in human lymphocytes isolated from 
humanized mice. Human lymphocytes in humanized mice were derived using stem cells from 5 different 
human donors, and isolated from humanized mice spleen 3 days after irradiation. After pooling samples to 
obtain sufficient cells, a total of 21 samples (0 Gy, n = 7; 1 Gy, n = 7; 2 Gy, n = 7) were analyzed for proteomic 
analysis. Dose response relationship of the best candidates (FDXR, BAX, DDB2, and ACTN1) in cells from each 
human donor is illustrated. Protein abundance quantified using TMT labeling was plotted by irradiation dose. 
Individual dose response curves from five human donors were plotted in dashed lines and colored symbols. 
Error bars in dose response curve of each donor were calculated from replicate measurements of pooled 
mice. Solid black line and circles depict the average dose response relationship. The error bar in averaged curve 
was calculated from data from 5 different donors. Data indicate mean ± SEM.
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Discussion
The identification of radiation-responsive proteins in blood samples that can rapidly and accurately quantify radi-
ation exposure up to a week post irradiation will be critical for the mass-screening of individuals after a large-scale 
radiological event. In this scenario it is unlikely that blood samples will be collected from all potentially exposed 
individuals within 24–48 h. There is no perfect model for radiation biodosimetry and biomarker development: 
radiotherapy cancer patients are limited in terms of fixed fractionation doses and confounders of chemotherapy 
and underlying disease whereas the large cost of NHPs largely precludes developmental and systematic studies 
for many research groups. As an alternative model, we have used the hematopoietically Hu-NSG mouse model to 
identify radiation-responsive protein biomarkers in human lymphocytes in vivo, 3 days after radiation exposure.
Mass spectrometry-based proteomics analysis has been used routinely for biomarker discovery in clinical 
research. Applications of proteome profiling in radiation research are increasing, particularly as the research aims 
to study not only protein expression, but also function, structure, modifications and interactions24. Recently, pro-
teomic changes in plasma and urine after irradiation of NHPs have also been studied14,15. In this study, we used 
global proteomics analysis to identify novel radiation biomarkers in X-irradiated human lymphocytes isolated 
from the Hu-NSG mouse spleen. We found a distinct protein signature 3 days post radiation exposure compared 
to the non-irradiated control group (Fig. 2). In total, 3,376 human proteins were identified of which 46 proteins 
were differentially expressed after radiation exposure. Twenty eight proteins were found up-regulated and 18 pro-
teins were found down-regulated (Table 1), which showed distinct separation between non-irradiated group and 
irradiated groups by supervised PCA (Fig. 2). Of the 46 radiation-responsive proteins, four up-regulated proteins 
FDXR, BAX, DDB2 and ACTN1 were considered as the top 4 candidates based on large fold changes >2 and a 
strong correlation between protein expression and irradiated dose (correlation coefficient >0.7; p value < 0.05). 
Increased expression of the candidate proteins from the irradiated humanized mice groups derived from different 
human stem cell donors showed a reliable dose dependent response to radiation exposure (Fig. 3), which supports 
the finding that the radiation-induced response of our top candidates might have low inter-individual variation.
The top four candidates identified here are known to be associated with radiation-induced apoptosis, DNA 
damage and cellular senescence. FDXR is a mitochondrial flavoprotein transferring electron from NADPH 
to cytochrome p450. It can be induced by DNA damage and is involved in p53 and oxidative stress-mediated 
apoptosis25,26. In transcriptomics studies, FDXR gene is known as one of the most radiation responsive mark-
ers27,28 and has been validated as a sensitive gene for dose assessment in two large scale studies on laboratory 
inter-comparison of gene expression5,29,30. The FDXR gene has also shown a significant dose response over a large 
range of radiation doses in ex vivo X-irradiated human blood and radiotherapy treated patients and discrimi-
nated pre-irradiated and 24 h post-irradiated samples from prostate cancer patients29,31,32. BAX is a well-known 
regulator in radiation-induced apoptosis33. Radiation exposure activates BAX protein through ATM and CHK2 
mediated p53 activation, leading to cytochrome c release and apoptotic cell death34. DDB2 is a protein associated 
with nucleotide excision repair and has a key role in DNA damage recognition. It facilitates ATM/ATR recruit-
ment to damage sites and leads to apoptosis by regulating p21 protein35. ACTN1 is an actin binding protein regu-
lating actin cytoskeleton36, and is one of the cellular senescence related proteins37,38. Chronic radiation exposure 
has been shown to cause premature senescence with an increase of ACTN1 in human umbilical vein endothelial 
cells39.
Our results (Table 2 and Supplementary Table S4) showed that combinations of FDXR, DDB2 and ACTN1 
proteins generate an accurate prediction of the radiation dose in human lymphocytes in vivo: their mean absolute 
errors were ≤0.13 Gy over the tested dose range of 0 to 2 Gy. Previous studies have similarly used a combinatorial 
approach of plasma protein markers to provide an improved dose assessment compared to a single biomarker 
alone in mouse10 and NHP models13. Budworth et al.40 showed that a 8-gene transcript panel of DNA repair 
markers (BBC3, FDXR, CDKN1A, GADD45a, PCNA, XPC, DDB2 and POLH) was able to discriminate radia-
tion exposure in the human ex vivo blood model and in vivo irradiated human blood samples obtained from 
patients who received total body irradiation, 24 h after irradiation40, whereas Manning and colleagues31, com-
bined FDXR and DDB2 gene expression response to produce the best dose estimate in human blood cells 24 h 
after X-irradiation (1 and 2 Gy). The notable finding in this study is that we used our 3-protein panel to predict 
dose 3 days after radiation. This has the potential to extend the window of time relevant for medical decision 
making for radiological triage.
Biomarker validation studies were performed to evaluate the radiation-induced response using indirect 
immunofluorescence assay protocols. Using available Hu-NSG peripheral blood samples, our initial validation 
studies focused on the FDXR protein biomarker. Consistent with the results of proteomic analysis in human 
Modela
Predicted dose (Mean ± SD, Gy)
coefficient b R2 (p value)b MAEc
Actual irradiated dose
0 Gy 1 Gy 2 Gy
Dose ~ FDXR + ACTN1 0.003 ± 0.050 1.06 ± 0.17 1.90 ± 0.24 0.95 ± 0.06 0.958 (<0.0001) 0.13
Dose ~ FDXR + ACTN1 + DDB2 0.001 ± 0.034 1.06 ± 0.14 1.91 ± 0.26 0.96 ± 0.06 0.959 (<0.0001) 0.12
Dose ~ FDXR + ACTN1 + BAX 0.001 ± 0.046 1.07 ± 0.16 1.90 ± 0.23 0.95 ± 0.06 0.958 (<0.0001) 0.13
Dose ~ FDXR + ACTN1 + DDB2 + BAX 0.13 ± 0.20 1.05 ± 0.14 1.91 ± 0.26 0.90 ± 0.06 0.942 (<0.0001) 0.15
Table 2. Dose prediction of candidate protein markers. aData obtained from proteomic analysis were used for 
investigating dose prediction. Ranks and specific values of all models were provided in Supplementary Table S4. 
bCoefficient, R2 and p value was obtained by linear regression analysis for predicted vs. actual doses. cMAE 
values were used as indicators to compare the difference between actual irradiated and predicted dose.
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CD45+ lymphocytes isolated from the mouse spleen, we observed a similar dose-dependent increase of total 
FDXR protein fluorescence in human CD45+ lymphocytes obtained from the peripheral mouse blood after X-ray 
exposure (Fig. 4A). Future studies using an independent validation data set for each biodosimetry marker will 
confirm the capability of our protein panel to accurately predict dose. Several studies to date have validated FDXR 
transcriptional gene expression in blood leukocytes ex vivo40,41 as a biomarker of radiation exposure, however few 
studies have validated this biomarker in vivo29,32. Recently, O’Brien et al.32 carried out an extensive study and pro-
vided for the first time physical and biological dose estimates using FDXR gene expression in human leukocytes 
from radiotherapy patients in vivo.
Previous studies by Amundson and others27,42,43 have successfully used the human ex vivo model to closely 
replicate the in vivo gene expression response to radiation. To assess radiation-induced response of protein mark-
ers in human lymphocytes irradiated ex vivo, we measured expression levels of our three best candidates, FDXR, 
DDB2 and ACTN1 protein, 3 days after initial exposure (Fig. 4B). Since NSG mice are relatively sensitive with a 
LD50/30 of ~ 3–4 Gy23, we irradiated human peripheral blood with a dose of 4 Gy γ rays ex vivo to represent the 
sensitivity of the Hu-NSG mouse response at 2 Gy. The results show an increase in expression of FDXR, DDB2 
and ACTN1, which allowed us to discriminate between non-irradiated and irradiated samples. Although there 
was no apparent large variation in biomarker response between human donors recruited here, it will be important 
to plan a population study in the future, to evaluate our protein panel and other top up and down regulated bio-
markers for the effects of individual factors (age, gender, smoking history etc.) after radiation exposure.
It is well-known that irradiated human lymphocytes undergo apoptosis in a time- and dose- dependent man-
ner44–46. Contrary to the in vivo model, where dying cells appear to be cleared from the circulation by the liver, the 
human blood ex vivo model represents a different microenvironment whereby biological processes and related 
measurements could be affected by artifacts such as increased DNA fragmentation and apoptosis, that could be 
a confounding factor in the day 3 cultures. To this end, future studies should aim to evaluate the dose-response 
relationship with extended doses and time kinetics for the top radio-responsive proteins and statistically compare 
the day 3 fold-changes with earlier and later time points up to a week post-exposure. Previous studies to date, have 
reported increased gene/protein expression of our candidate biomarkers 24–48 h after radiation exposure32,40,41,47, 
whereas less is known about the longer time points. In the present work, we have combined the humanized mouse 
model and the human ex vivo model to investigate candidate protein biomarkers in human blood leukocytes 
after acute radiation exposure. Future studies designed to verify and validate the candidate proteins identified 
here, provide the opportunity to develop a biodosimetry assay for use in rapid, early triage following a large scale 
radiological incident or accident.
Figure 4. Verification of candidate protein expression in human lymphocytes. (A) Protein expression levels 
in human lymphocytes in vivo. Left panel shows representative images of FDXR stained human CD45+ 
lymphocytes after exposure to X rays (0 and 2 Gy). Right panel shows quantified FDXR expression level in 
human CD45+ cells from humanized mouse blood. Fluorescence intensity of FDXR was quantified and was 
analysed by Kruskall-Wallis test and Dunn’s post hoc multiple comparison test. Data indicate mean ± SEM. 
Asterisk (*) means statistically significant difference from control group (p value < 0.05). (B) Protein expression 
levels in human lymphocytes in vitro. FDXR, DDB2 and ACTN1 protein expression levels were measured in 
human lymphocytes cultured for 3 days after irradiation (0 and 4 Gy). Fold change of each protein level was 
calculated based on control. Data indicate mean ± SEM and analysed by Student’s t-test. Asterisk (*) means 
statistically significant difference from non-IR group (p value < 0.05).
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Summary
To our knowledge, this is the first study that has used the hematopoietically Hu-NSG model for biological radi-
ation dosimetry studies. Results show that the Hu-NSG mice were successfully engrafted with HSCs to pro-
duce human hematopoietic progenitor and differentiated cells for proteomic study. Our goal was to identify 
protein markers for radiation biodosimetry 3 days after radiation exposure in vivo. Three proteins (FDXR, 
DDB2 and ACTN1) were determined as the best candidate markers and combined expression of these three 
proteins predicted more accurately the absorbed dose than either one alone. The fact that we have identified 
known radiation-responsive proteins in vivo as candidate biomarkers in human lymphocytes to accurately pre-
dict radiation dose, 3 days after acute radiation exposure supports the use of the humanized mouse model for 
the development of biodosimeters for use in radiation triage. Further studies are needed to optimize and validate 
our biomarker panel to estimate retrospective dose up to a week after exposure and to advance high-throughput 
screening methods for the rapid immunodetection of radiation-responsive biomarkers in blood samples for radi-
ological triage.
Methods
All methods were carried out in accordance with relevant guidelines and regulations.
Humanized mice model. All animal experiments were approved by the Columbia University Institutional 
Animal Care and Use Committee (IACUC; approved protocol AAP9613) and were conducted under all relevant 
federal and state guidelines. Female immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson 
Laboratory; Bar Harbor, ME, USA), aged 6 to 8 weeks, were engrafted with commercially available human cord 
blood CD34+ cells (Cincinnati Children’s Hospital Medical Center; Cincinnati, OH, USA). For the engraftment, 
the NSG mice were irradiated with 2.0 Gy of gamma rays followed by injection of 200,000 human CD34+ cells 
(n = 5 human donors) in the mouse tail vein within 24 hours after the irradiation. Human cell engraftment was 
determined four months later by flow cytometry using 20 μl of mouse tail vein blood, stained with antibodies spe-
cific to human CD45, (WBC marker, clone HI30, Biolegend, San Diego, CA), human CD3 (T cell marker, clone 
UCHT1; Biolegend), human CD20 (B cell marker, clone 2H7; Biolegend) and mouse CD45, (WBC marker, clone 
30-F11, eBioscience, San Diego, CA). The study was designed using two cohorts of humanized mice engrafted 
with 5 different donors of human CD34+ cells. Cohort 1 (16 mice) were injected with donors #1–3 and Cohort 
2 (17 mice) with donors #4–5.
Irradiation. The humanized mice used here are relatively radiosensitive with a LD50 of about 3~4Gy23. As a 
result, this proteomics study was designed for 1 Gy and 2 Gy doses in vivo model. X-irradiation was performed 
using X-RAD 320 biological irradiator (Precision X-ray, North Branford, CT) operating at 320Kv, 12.5 mA. Total 
33 humanized mice were randomly grouped and irradiated with 0, 1 and 2 Gy (0 Gy, n = 7; 1 Gy, n = 11; 2 Gy, 
n = 15) at a dose rate of 88 cGy/min. Spleen and blood samples were collected 3 days after irradiation for pro-
teomic analysis and immunofluorescence assay.
Sample preparation for proteomic analysis. Spleens were homogenized and filtered through 40μm 
nylon strainer to obtain a single cell suspension. Cells were resuspended in autoMACS Rinsing Solution (Miltenyi 
Biotec, Bergisch Gladbach, Germany) with MACS BSA stock solution (Miltenyi Biotec). Small portion of cells 
were first stained with human CD45 clone HI30, human CD3 clone UCHT1, human CD20 clone 2H7, and 
mouse CD45 clone 30-F11. Cell numbers in each spleen sample were measured with LSR Fortessa Cell Analyzer 
(BD Biosciences, San Jose, CA) and data were analysed with FlowJo software (Tree Star, Inc., San Carlos, CA). 
Based on the cell number, whole spleen cell suspension was incubated with human CD45 antibody (Clone HI30). 
Human CD45+ cells were collected in PBS by FACS Aria (BD Biosciences). To obtain enough cell number for 
proteomic analysis, samples were pooled based on the number of collected cells by flow cytometry. After pooling 
samples, total 21samples (0 Gy, n = 7; 1 Gy, n = 7; 2 Gy, n = 7) were prepared for proteomic analysis. Cell pellets 
were frozen and stored at −80 °C until use.
Protein Extraction and Digestion. Each cell pellet was homogenized in lysis buffer (4 M Urea in 50 mM 
Ammonium Bicarbonate, 0.1% RapiGestTM; Waters, MA) and Roche protease inhibitor cocktail) and protein 
concentration was measured by the Qubit Protein Quantification Assay (Thermo Fisher Scientific, Rockford, 
IL). An equal amount of protein lysate from each sample was pooled as a common reference to generate ratios in 
the TMT10plex labeling experiment. 15 μg of protein lysates were reduced with 10 mM TCEP and alkylated with 
iodoacetamide (18.75 mM) in the dark for 30 minute. Protein was precipitated by the methanol-chloroform pro-
tocol and re-suspended in 100 mM TEAB. 375 ng of trypsin was added to the protein extract in a 1:40 enzyme to 
protein ratio and incubated for 16 hours at 37 °C. Next day, samples were centrifuged for 30 min at 14,000 rpm to 
remove insoluble materials and 0.6 μg of the peptide mixture was used for peptide quantification assay (Thermo 
Fisher Scientific).
Tandem Mass Tagging Labeling. Isobaric labeling of digested protein lysates was performed using the 
10-plex tandem mass tag (TMT) reagents (Thermo Fisher Scientific). TMT reagents (0.8 mg) were dissolved in 
41 μl of dry acetonitrile (ACN), and 7.5 μl was added to 15 μg of digested lysate in 100 mM TEAB. After 1 hour 
incubation at room temperature, the reaction was quenched by adding 3 μl of 5% hydroxylamine. Labeled pep-
tides were combined and dried for the subsequent high pH reverse phase peptide fractionation (Thermo Fisher 
Scientific). Eight fractions were generated for each combined set.
LC-MS/MS Analysis. Each TMT labeled fraction was reconstituted in a solution of 2%ACN, 2% formic acid 
(FA) for MS analysis. Peptides were eluted from the easy-spray column (50 cm) using a Dionex Ultimate 3000 
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Nano LC system with a 30 min gradient from 5% buffer B to 20% buffer B (100% ACN, 0.1% FA) and 10 min 
gradient from 20%B to 30%B. The gradient was switched from 30% to 85% buffer B over 1 min and held constant 
for 3 min. Finally, the gradient was changed from 85% buffer B to 98% buffer A (100% water, 0.1% FA) over 1 min, 
and then held constant at 98% buffer A for 20 minutes. The application of a 2.0 kV distal voltage electrosprayed 
the eluting peptides directly into the Thermo Fusion Tribrid mass spectrometer equipped with an EASY-Spray 
source (Thermo Fisher Scientific). Mass spectrometer-scanning functions and HPLC gradients were controlled 
by the Xcalibur data system (Thermo Finnigan, San Jose, CA).
For all experiments, the instrument was operated in the data-dependent mode. We collected FTMS1 spec-
tra at a resolution of 120 K with an automated gain control (AGC) 400,000, a max injection time of 50 ms. The 
10 most intense ions were selected for MS/MS. Precursors were filtered according to charge state (z = 2–7), 
and monoisotopic peak assignment. Previously interrogated precursors were excluded using a dynamic exclu-
sion duration of 60 s. For the FTMS3 method, ITMS2 spectra were collected at AGC of 100,000, max injec-
tion time of 105 ms, and CID collision energy of 35%. FTMS3 spectra utilized the same Orbitrap parameters as 
FTMS2 method, except HCD collision energy was increased to 55% to ensure maximal TMT report ion yield. 
Synchronous-precursor-selection (SPS) was enabled to include up to 3, 6, or 10 MS2 fragment ions in the FTMS3 
scan.
Database Search and Assignment of MS/MS Spectra. Tandem mass spectra from raw files were 
searched against a human protein database using the Proteome Discoverer 2.1 (Thermo Finnigan). The Proteome 
Discoverer application extracts relevant MS/MS spectra from the raw file and determines the precursor charge 
state and the quality of the fragmentation spectrum. The Proteome Discoverer probability-based scoring system 
rates the relevance of the best matches found by the SEQUEST algorithm. The human protein database was down-
loaded as FASTA-formatted sequences from UniProt protein database (released in October, 2016). The peptide 
mass search tolerance was set to 10ppm. A minimum sequence length of 7 amino acids residues was required. 
Only fully tryptic peptides were considered. To calculate confidence levels and FDR, Proteome Discoverer gen-
erates a decoy database containing reverse sequences of the non-decoy protein database and performs the search 
against this concatenated database (non-decoy + decoy). 5% FDR was used to generate the quantitative list for 
statistical analysis.
Determination of TMT Reporter Ion Intensities and Quantitative Data Analysis. For quantifica-
tion, a 0.003 m/z (10plex TMT) window centered on the theoretical m/z value of each reporter ion was queried 
for the nearest signal intensity. Reporter ion intensities were adjusted for the isotopic impurities of each TMT rea-
gent according to the manufacture specifications. The signal-to-noise (S/N) values for all peptides were summed 
within each TMT channel, and each channel was scaled according to the inter channel difference of these sums 
to account for differences in sample handling. For each peptide, a total minimum sum S/N of 10 and an isolation 
purity greater than 75% was required. Total peptide amount was used for normalization to correct for experimen-
tal bias. Using the Qlucore Omics Explorer 2.2 (Qlucore AB, Lund, Sweden), ANOVA was applied to generate a 
protein signature from each comparison. Multiple test correction was performed by adjusting the calculated p 
values according to Benjamini-Hochberg method.
Immunofluorescence assay in humanized mouse model. Peripheral mononuclear cells (PBMCs) 
were isolated from blood samples of humanized mice (generated from 2 different human stem cell donors) by 
the Ficoll density gradient method. Whole blood samples were diluted to RPMI medium (Gibco, Waltham, MA), 
layered on Histopaque1083 (Sigma-Aldrich, St. Louis, MO), and centrifuged at 1220 rpm for 45 min. The buffy 
coat of PBMCs was taken and washed with PBS. To label human CD45+ cells, the isolated PBMC cells were 
incubated with rat anti-human CD45 (Thermo Fisher Scientific) for 30 min and fixed with 2% paraformaldehyde 
(Electron Microscopy Sciences, Hatfield, PA) for 20 min. Cells were washed with PBS and cytospun (Cytospin 
4; Thermo Scientific, Waltham, Boston, MA) onto coated microscope slides (CYTOSLIDE™; Thermo Scientific) 
and then placed into PBS. For candidate biomarker staining, cells on the slides were treated with 0.5% Triton-X 
100, blocked with 3% bovine serum albumin (Sigma-Aldrich) and incubated with the following antibodies: rab-
bit anti-FDXR (Sigma-Aldrich), Alexa fluor 555 goat anti-rabbit IgG (Thermo Fisher Scientific) and Alexa fluor 
488 goat anti-rat IgG (Thermo Fisher Scientific). Cells were counterstained and mounted with VECTASHIELD 
Antifade Mounting Medium with DAPI (Vector laboratories, Burlingame, CA). Quantification of FDXR pro-
tein levels was performed using image analysis software described previously48 with the following modification: 
human lymphocytes were identified and selected from binarized images for human CD45 using Otsu’s algo-
rithm49. Fluorescence values from a second image, corresponding to the immunostaining for FDXR, were inte-
grated over the cellular area. Fluorescence intensity values were background subtracted, normalized to the cellular 
area and reported as bits/pixel.
Immunofluorescence assay in human lymphocytes in vitro. Research was approved by the 
Columbia University Medical Center Institutional Review Board (IRB-AAAF2671) and informed written 
consent was obtained from all participants. Peripheral whole blood samples from healthy human volunteers 
were collected in heparin tube and irradiated with γ rays (0 and 4 Gy) using a Gammacell 40 137Cs irradiator 
(Atomic Energy of Canada, Ltd.). Peripheral blood was incubated in RPMI 1640 (Gibco) with 15% FBS and 
2% Penicillin and Streptomycin at 37 °C. PBMCs were isolated from cultured blood samples (n = 3 ~ 4) 3 days 
after radiation exposure and were prepared for immunofluorescent labeling using the same protocol described 
above in the humanized mice model. Cells were incubated with the following antibodies: rabbit anti-FDXR, 
rabbit anti-DDB2 (Thermo Fisher Scientific), rabbit anti-ACTN1 (Cell Signaling Technology, Danvers, MA), and 
Alexa fluor 488 goat anti-rabbit IgG. Fluorescence levels of candidate proteins and percentages of positive cells 
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based on maximum pixel intensity were measured and fold changes compared to baseline level were calculated. 
Quantification of radiation-induced protein expression levels was determined in non-apoptotic cells only by the 
image analysis software program48, such that advanced apoptotic cells observed as a gross change in area and 
morphology of the DAPI-labeled nuclei, were not included for analysis.
Statistical analysis. Statistical analysis was performed using R software (version 3.4.0; https://
www.r-project.org/) and GraphPad Prism (version 6.01; GraphPad Software, Inc., La Jolla, CA). Protein expres-
sion levels of radiation responsive proteins identified in proteomic analysis were further analysed to find best 
candidate markers and panels. Correlation between irradiated dose and protein abundance were analysed by 
Pearson correlation coefficients. Multiple linear regression analysis was used to develop dose-response relation-
ship for protein combination for dose assessment. The best fitted model for each parameter was applied to pooled 
dataset to estimate irradiation dose. We used Akaike Information Criterion (AIC)-based method to compare 
all single/combination models. AICc score, a corrected value of AIC for small sample size, and Akaike weight 
for each model was computed to determine the best model for dose prediction. The capability of candidates to 
predict dose was compared using mean absolute error (MAE) of predicted dose vs. actual dose. Possible influ-
ence by different experimental batches or cohorts were controlled by statistical analysis using batch variables or 
normalizing data with Succinate dehydrogenase [ubiquinone] flavoprotein subunit (SDHA), one of endogenous 
controls. There was no significant difference in SDHA level between different dose groups, and SDHA normal-
ization did not affect the results obtained from original dataset. FDXR fluorescence intensity was compared by 
Kruskall-Wallis test and Dunn’s post hoc test. Fold changes of each candidate protein were compared by Student’s 
t-test. Two-tailed p values less than 0.05 were considered statistically significant.
Data Availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Dataset & Information files.
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